Clinical trial
Phase II Study of Neoadjuvant Atezolizumab-based Immunotherapy for Patients With Urothelial Carcinoma (NEBULA)
NCT02451423 is registered in ClinicalTrials.gov with Lawrence Fong as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Neoadjuvant Atezolizumab-based Immunotherapy for Patients With Urothelial Carcinoma (NEBULA)
- Lead sponsor
- Lawrence Fong
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 29, 2016
- Completion date
- March 31, 2023
- Enrollment
- 23 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.